# EMCURE (EMCURE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/emcure

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,981
- Change: +3.73%
- As of: 2026-09-18
- 1D return: +4.92%
- 5D return: +2.09%
- 1M return: +6.51%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, EMCURE's technical posture indicates a bullish trend on the daily and weekly timeframes, supported by prices trading above key moving averages and a bullish Supertrend signal. However, the monthly timeframe presents a conflicting bearish Supertrend signal, suggesting potential headwinds despite shorter-term strength. The stock is trading near its recent high, with the nearest resistance identified at ₹2048.0, approximately 2.21% above the current price of ₹2003.8. Key support levels are observed around ₹1985.07 (0.93% below) and ₹1962.73 (2.05% below).

Recent activity includes a "Morning Star" pattern formation on the daily chart, often interpreted as a bullish reversal signal. On September 18, 2026, an "EXTREME" severity anomaly was noted, with a significant volume increase (12.63 times the average) accompanying a small upward price move (0.05%). This suggests strong buying interest, though it occurred after a "HIGH" severity downward gap on September 17, 2026. The stock's annualized volatility stands at 37%, and its maximum drawdown has been 39%, indicating a risk profile to consider.

The alignment across timeframes is mixed. Daily and weekly trends are bullish, with prices above their respective 20-day and 50-day moving averages and Supertrend indicators. Conversely, the monthly Supertrend is bearish, and the price is below the monthly Supertrend level of ₹2101.8. This divergence warrants close observation.

- Daily and weekly timeframes show a bullish trend, with prices above key moving averages and Supertrend.
- Monthly timeframe exhibits a bearish Supertrend signal, indicating a potential conflict with shorter-term trends.
- Nearest resistance is at ₹2048.0 (2.21% above current price); nearest support is at ₹1985.07 (0.93% below).
- A daily "Morning Star" pattern and an extreme volume anomaly on September 18, 2026, suggest potential upward momentum.
- Watch for a sustained break above ₹2048.0 for bullish confirmation or a move below ₹1985.07 to test further support levels.

- Morning Star
- Doji
- Bearish Engulfing Reversal
- Inside Bar

### News Context

During the week ending September 16, 2026, Emcure Pharmaceuticals was highlighted in multiple market reports as a stock of interest. On September 15, 2026, Motilal Oswal Wealth Management Research recommended Emcure Pharmaceuticals as a top stock to buy for the week. Similarly, on the same day, Sudeep Shah, Head of Technical & Derivatives Research at an unnamed entity, also listed Emcure Pharmaceuticals among top stocks to buy for the week of September 15-18, 2026. Separately, on September 16, 2026, Emcure Pharma was mentioned in a "Trade Spotlight" article discussing how to trade various stocks, including Emcure Pharma, on that date.

- On September 15, 2026, Motilal Oswal Wealth Management Research identified Emcure Pharmaceuticals as a recommended stock for the week.
- On September 15, 2026, Sudeep Shah recommended Emcure Pharmaceuticals as a top stock to buy for the week of September 15-18, 2026.
- On September 16, 2026, Emcure Pharma was included in a "Trade Spotlight" article.

- Trade Spotlight: How should you trade Dabur India, ACME Solar Holdings, Emcure Pharma, Aegis Vopak Terminals, Prime Focus, and others on September 16?
- Nifty faces risk of retesting June lows as rising US yields and crude oil prices remain key headwinds
- Stock Market Live Updates Today: BSE Sensex rallies 400 points, Nifty climbs above 23,500 in early trade - The Times of India
- Top stocks to buy: Stock recommendations for September 15, 2026 week - check list
- Stocks to buy: What's the outlook for Nifty for September 15-September 18 week? Check list of top stock recommendations

### What Changed

Emcure Pharmaceuticals (EMCURE) on the NSE experienced a price increase to ₹2003.8 as of the observation date September 18, 2026, up from ₹1909.8 previously. The evidence does not provide earlier context for weekly or daily trends, nor does it contain any new filings or news developments for the period.

- On September 18, 2026, Emcure Pharmaceuticals' stock price was ₹2003.8.
- The stock price on the preceding observation date was ₹1909.8.

### Official Filings

Emcure Pharmaceuticals Limited has announced several key developments. The company's Nomination and Remuneration Committee approved the allotment of 11,400 equity shares on September 11, 2026, under its ESOP/ESPS plan, which resulted in a slight increase in the company's paid-up share capital and total number of shares. The company also confirmed a dividend of ₹3.60 per share, with a record date of September 4, 2026. In preparation for its 45th Annual General Meeting (AGM) on September 21, 2026, Emcure dispatched letters to shareholders who had not registered their email addresses, providing access to the Annual Report 2025-26 and the AGM notice. The FY 2025-26 annual report indicated significant growth, with revenue from operations increasing by 16.6% to ₹92,035 million, crossing the USD 1 billion mark. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were ₹17,886 million, with a margin of 19.4%, and Profit After Tax (PAT) grew by 33.1% to ₹9,413 million. The company also reported that its USFDA inspection at the Sanand facility concluded with a Voluntary Action Indicated (VAI) classification.

- On September 11, 2026, Emcure Pharmaceuticals allotted 11,400 equity shares under its ESOP/ESPS plan, increasing paid-up share capital to ₹1,897,106,470.
- A dividend of ₹3.60 per share was declared, with a record date of September 4, 2026.
- For the fiscal year ended March 31, 2026, revenue from operations grew 16.6% to ₹92,035 million, EBITDA was ₹17,886 million (19.4% margin), and PAT was ₹9,413 million (up 33.1%).
- The 45th Annual General Meeting is scheduled for September 21, 2026, to be held via video conferencing.
- The USFDA inspection at the Sanand formulations facility was classified as Voluntary Action Indicated (VAI) and is now closed.

- Emcure Pharmaceuticals Limited has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL
- SERIES:EQ |PURPOSE:DIVIDEND - RS 3.60 PER SHARE |FACE VALUE:10 |RECORD DATE:04-Sep-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
- Intimation under Regulations 30 and 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dispatch of letter to the Members whose e-mail addresses are not registered with the Company/Depository Participants |SUBJECT: General Updates
- EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Emcure Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026 |SUBJECT: Shareholders meeting
- EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 21-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- AS ON DATE : 28-AUG-26
- EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Emcure Pharmaceuticals Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Update on USFDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, India. |SUBJECT: General Updates

### Fundamentals

Emcure Pharmaceuticals reported a steady increase in its revenue from operations over the three quarters ending Q1 FY2026-27. Revenue grew from ₹2,363.48 crore in Q3 FY2025-26 to ₹2,580.45 crore in Q1 FY2026-27. This top-line growth was accompanied by an improvement in profitability. Profit Before Tax (PBT) rose from ₹313.79 crore in Q3 FY2025-26 to ₹393.53 crore in Q1 FY2026-27. Consequently, Profit Loss For Period (Net Profit) also showed an upward trend, increasing from ₹231.37 crore to ₹292.49 crore over the same periods. The company's finance costs fluctuated, decreasing to ₹31.54 crore in Q1 FY2026-27 from ₹46.40 crore in Q4 FY2025-26. Tax expenses generally moved in line with profits. The company's Paid Up Value Of Equity Share Capital remained relatively stable, indicating no significant equity dilution or issuance during these periods.

- Revenue from operations increased sequentially from ₹2,363.48 crore in Q3 FY2025-26 to ₹2,580.45 crore in Q1 FY2026-27.
- Profit Before Tax grew from ₹313.79 crore in Q3 FY2025-26 to ₹393.53 crore in Q1 FY2026-27.
- Net Profit (Profit Loss For Period) rose from ₹231.37 crore in Q3 FY2025-26 to ₹292.49 crore in Q1 FY2026-27.
- Finance Costs decreased to ₹31.54 crore in Q1 FY2026-27 from ₹46.40 crore in Q4 FY2025-26.
- Paid Up Value Of Equity Share Capital remained stable, reported at ₹189.68 crore in Q1 FY2026-27.

### Bull Case

Emcure Pharmaceuticals' (Emcure) stock is showing several technical indicators that suggest a constructive outlook. On a daily timeframe, the stock's closing price of ₹2003.8 is above its 20-day Exponential Moving Average (EMA) of ₹1925.47 and its 50-day Simple Moving Average (SMA) of ₹1903.24. The upward slope of these moving averages, particularly the 20-day EMA's slope of 24.39, indicates positive momentum. The Supertrend indicator is also showing a bullish signal at ₹1844.5. On a weekly basis, the trend remains bullish with the Supertrend at ₹1625.63, and the 20-day EMA at ₹1838.19 is trending upwards with a slope of 63.75. Additionally, Emcure Pharmaceuticals has been recommended as a top stock to buy by external research firms in recent weeks.

- On September 18, 2026, Emcure Pharmaceuticals' closing price of ₹2003.8 was above its 20-day EMA (₹1925.47) and 50-day SMA (₹1903.24).
- The daily Supertrend indicator signaled a bullish trend at ₹1844.5 as of September 18, 2026.
- The weekly Supertrend indicator was also bullish at ₹1625.63.
- Emcure Pharmaceuticals was listed as a top stock recommendation by Motilal Oswal Wealth Management and Sudeep Shah (Head) in September 2026.

- Trade Spotlight: How should you trade Dabur India, ACME Solar Holdings, Emcure Pharma, Aegis Vopak Terminals, Prime Focus, and others on September 16?
- Nifty faces risk of retesting June lows as rising US yields and crude oil prices remain key headwinds
- Stock Market Live Updates Today: BSE Sensex rallies 400 points, Nifty climbs above 23,500 in early trade - The Times of India
- Top stocks to buy: Stock recommendations for September 15, 2026 week - check list
- Stocks to buy: What's the outlook for Nifty for September 15-September 18 week? Check list of top stock recommendations

### Bear Case

The company's monthly trend analysis indicates a bearish Supertrend at 2101.8, suggesting potential downward pressure over a longer timeframe. While the daily trend shows a bullish Supertrend at 1844.5, the monthly view presents a cautionary signal. The stock has experienced a maximum drawdown of -39%, indicating significant past volatility. Additionally, the market context highlights broader headwinds such as rising US yields and crude oil prices, which could impact the broader market and potentially Emcure Pharmaceuticals.

- Monthly trend analysis shows a bearish Supertrend reading of 2101.8 as of 2026-09-18.
- The stock has recorded a maximum drawdown of -39%.
- Broader market headwinds include rising US yields and crude oil prices, as noted on September 16, 2026.

- Trade Spotlight: How should you trade Dabur India, ACME Solar Holdings, Emcure Pharma, Aegis Vopak Terminals, Prime Focus, and others on September 16?
- Nifty faces risk of retesting June lows as rising US yields and crude oil prices remain key headwinds
- Stock Market Live Updates Today: BSE Sensex rallies 400 points, Nifty climbs above 23,500 in early trade - The Times of India
- Top stocks to buy: Stock recommendations for September 15, 2026 week - check list
- Stocks to buy: What's the outlook for Nifty for September 15-September 18 week? Check list of top stock recommendations

### FAQs

**What were Emcure Pharmaceuticals' key financial results for the fiscal year ending March 31, 2026?**

For the fiscal year 2025-26, Emcure Pharmaceuticals reported revenue from operations of INR 92,035 million, an increase of 16.6% year-over-year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were INR 17,886 million, with an EBITDA margin of 19.4%, an improvement of 80 basis points. Profit After Tax (PAT) grew by 33.1% to INR 9,413 million. The company noted that domestic business revenue increased by 10% to INR 40,270 million, while international revenue grew by 22.2% to INR 51,766 million. Research and Development (R&D) investment was INR 3,835 million, representing 4.2% of sales.

**What corporate actions has Emcure Pharmaceuticals undertaken recently?**

Emcure Pharmaceuticals announced the allotment of 11,400 equity shares under its ESOP/ESPS plan on September 11, 2026. This allotment increased the company's paid-up share capital to INR 1,897,106,470 and the number of paid-up shares to 189,710,647. Additionally, the company declared a dividend of ₹3.60 per share, with a record date of September 4, 2026.

**What is the current technical trend for Emcure Pharmaceuticals?**

As of September 18, 2026, the daily trend for Emcure Pharmaceuticals is indicated as bullish, with the Supertrend indicator at 1844.5. The closing price was ₹2003.8, which is above the 20-day Exponential Moving Average (EMA) of ₹1925.47 and the 50-day EMA of ₹1890.69. However, the monthly trend is indicated as bearish, with the Supertrend at ₹2101.8 and the 14-day Average Directional Index (ADX) at 39.43, suggesting strong momentum but a potential reversal point.

**When is Emcure Pharmaceuticals' Annual General Meeting (AGM) scheduled?**

Emcure Pharmaceuticals' 45th Annual General Meeting (AGM) is scheduled to be held via video conferencing on Monday, September 21, 2026, at 11:00 a.m. IST.

- Trade Spotlight: How should you trade Dabur India, ACME Solar Holdings, Emcure Pharma, Aegis Vopak Terminals, Prime Focus, and others on September 16?
- Nifty faces risk of retesting June lows as rising US yields and crude oil prices remain key headwinds
- Stock Market Live Updates Today: BSE Sensex rallies 400 points, Nifty climbs above 23,500 in early trade - The Times of India
- Top stocks to buy: Stock recommendations for September 15, 2026 week - check list
- Stocks to buy: What's the outlook for Nifty for September 15-September 18 week? Check list of top stock recommendations
- Emcure Pharmaceuticals Limited has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL
- SERIES:EQ |PURPOSE:DIVIDEND - RS 3.60 PER SHARE |FACE VALUE:10 |RECORD DATE:04-Sep-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
- Intimation under Regulations 30 and 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dispatch of letter to the Members whose e-mail addresses are not registered with the Company/Depository Participants |SUBJECT: General Updates
- EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Emcure Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026 |SUBJECT: Shareholders meeting
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,913.93
- Risk regime: Price Risk Currently Contained

### Support levels
- 1912.5
- 1627.4
- 1497.1

### Resistance levels
- 2048

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +4.92% |
| return_10 | +8.04% |
| return_1m | +6.90% |
| return_1y | +49.44% |
| return_20 | +6.51% |
| return_3m | +14.29% |
| return_5 | +2.09% |
| return_6m | +30.84% |
| return_since_start | +37.22% |
| return_ytd | +42.94% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -38.74% |
| annualized_volatility | +36.55% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Profit Rise Sharply, with Profit Growth Outpacing Revenue

Emcure Pharmaceuticals reported revenue of ₹2,580.45 crore for the first quarter of FY2026-27, a 22.85% increase from the same quarter last year. Net profit rose 36.17% to ₹292.49 crore, growing faster than revenue. The bottom-line expansion was supported by a lower effective tax rate and, on a sequential basis, a sharp decline in finance costs. Earnings per share increased to ₹15.50 from ₹10.92 a year ago.

## Revenue Growth

Revenue from operations reached ₹2,580.45 crore in Q1 FY2026-27, continuing an upward trajectory across the past five consecutive quarters. Sequential growth from Q4 FY2025-26 was 4.48% (₹110.74 crore), while year-over-year growth stood at 22.85% (₹479.91 crore). Other income was minimal at ₹2.07 crore.

## Profitability and Tax Rate

Profit before tax (PBT) increased to ₹393.53 crore, up 15.34% sequentially and 35.35% year-over-year. Net profit (profit for the period) rose to ₹292.49 crore, up 20.00% sequentially and 36.17% year-over-year. The faster growth in net profit relative to revenue indicates improved profitability. 

The effective tax rate declined from 28.56% in Q4 FY2025-26 to 25.67% in Q1 FY2026-27, contributing to the net profit increase. On a year-over-year basis, the tax rate also eased slightly from 26.13% to 25.67%.

## Expense Movements

Reported operating expenses for the quarter included cost of materials consumed at ₹481.14 crore, employee benefit expense at ₹409.50 crore, and depreciation and amortisation at ₹109.51 crore. 

Finance costs were ₹31.54 crore, marking a 32.04% sequential decline from ₹46.40 crore in the prior quarter, though they remained 17.87% higher than the year-ago quarter’s ₹26.76 crore. Tax expense increased 3.69% sequentially to ₹101.03 crore and rose 33.00% year-over-year, broadly tracking pre-tax profit growth.

## Earnings Per Share

Basic and diluted earnings per share both stood at ₹15.50 for Q1 FY2026-27, compared to ₹12.84 in Q4 and ₹10.92 in the year-ago quarter. This represents a 20.72% sequential increase and a 41.94% year-over-year increase. The year-over-year EPS growth exceeded the 36.17% growth in net profit.

## Other Comprehensive Income

Other comprehensive income (OCI) was ₹20.67 crore in Q1, down from ₹33.04 crore in Q4 and significantly lower than ₹79.57 crore in Q1 last year. Combined with net profit, total comprehensive income reached ₹313.16 crore, compared to ₹276.77 crore in Q4 and ₹294.37 crore in Q1 FY2025-26. Total comprehensive income grew 13.1% sequentially and 6.4% year-over-year despite the decline in OCI.

## Management Commentary

Management highlighted that FY27 is the second year of its five-year plan, focused on delivery, and Q1 results are an encouraging early signal. Revenue grew 22.8% YoY to INR 25,804 Mn, driven by strong international performance (up 34.2%) and resilient domestic growth (up 10.2%). EBITDA margin improved 50 bps to 19.7% due to productivity gains and operating leverage, while PAT grew 36.2% to INR 2,925 Mn. Management expects continued growth over the full year, supported by a strengthened team, portfolio traction, and a robust product pipeline. Recent strategic moves include licensing a novel anti-HPV candidate from ICMR and signing a voluntary licensing agreement with MSD for a generic once-monthly oral HIV PrEP pill, reinforcing the company's commitment to expanding its women's health and global access portfolios.

## Key Takeaway

Emcure Pharmaceuticals delivered a quarter of substantial year-over-year revenue and profit growth, with profit expanding faster than revenue. The improvement was supported by a lower effective tax rate and a sequential decline in finance costs. Earnings per share rose to ₹15.50, reflecting the stronger bottom line. While other comprehensive income declined, total comprehensive income still grew 6.4% year-over-year. The quarter continues a consistent upward revenue trend and demonstrates improved profitability.

### Ratios

## Official filings

- 2026-09-11 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_19900_WebXMLFile_20260911_165013818.xml)
- 2026-09-03 — Corporate Action Notice: Emcure Pharmaceuticals Limited - Ex-Date: 04-Sep-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-09-01 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_01092026162213_EPLReg36DispatchLettercontainingweblinkAnnual_Report.pdf)
- 2026-09-01 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19900_WebXMLFile_20260901_160856812.xml)
- 2026-08-28 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_28082026210104_SEIntimationAGMNoticeAnnualReport.pdf)
- 2026-08-28 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_19900_WebXMLFile_20260828_210504385.xml)
- 2026-08-27 — Annual Report: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_30805_EMCURE_2025_2026_A_12375514_28082026205921.pdf)
- 2026-08-12 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19900_WebXMLFile_20260812_184247602.xml)
- 2026-08-12 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_12082026182451_TranscriptofEarningCallQ1FY27.pdf)
- 2026-08-08 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_08082026101631_UpdateonUSFDASanand.pdf)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_07082026185050_NewspaperAdvertisementFSQ1FY27.pdf)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_07082026192914_IntimationOfAnalystMeet07082026.pdf)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_07082026192115_IntimationOfAnalystMeet07082026.pdf)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19900_WebXMLFile_20260807_194246351.xml)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_07082026193722_IntimationOfAnalystMeet07082026.pdf)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_07082026192418_IntimationOfAnalystMeet07082026.pdf)
- 2026-08-07 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_07082026191649_IntimationOfAnalystMeet07082026.pdf)
- 2026-08-06 — Generic Announcement: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19900_WebXMLFile_20260806_220357607.xml)
- 2026-08-06 — Generic Announcement: On August 6, 2026, Emcure Pharmaceuticals Limited's Board of Directors approved changes including Mr. Berjis Desai ceasing to be Chairman and Director effective conclusion of the ensuing AGM, Mr. Raghu Kumar's appointment as Additional Director and Independent Director effective August 6, 2026, and Mr. Satish Mehta's appointment as Chairman effective conclusion of the ensuing AGM. Mr. Desai is stepping down due to his appointment to the National Commission for Minorities. Mr. Mehta is the father of Whole-time Directors Mr. Samit Mehta and Mrs. Namita Thapar. — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_06082026140926_SEIntimationChangeinManagement.pdf)
- 2026-08-06 — Generic Announcement: Emcure Pharmaceuticals Limited's Board of Directors met on August 06, 2026, approving the unaudited financial results for the quarter ended June 30, 2026. The board also noted the retirement of Chairman Mr. Berjis Desai due to his appointment to the National Commission for Minorities, with Mr. Satish Mehta to succeed him as Chairman post-AGM. Additionally, Mr. Raghu Kumar was appointed as an Additional Director, and Mr. Samit Mehta was appointed as Chief Operating Officer. — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_06082026134140_OutcomeofBMQ1FY27F.pdf)
- 2026-08-06 — Management Change: Emcure Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_19900_WebXMLFile_20260806_153409144.xml)
- 2026-08-06 — Generic Announcement: Emcure Pharmaceuticals Limited will hold its 45th Annual General Meeting on September 21, 2026, to approve a final dividend of Rs. 3.60 per equity share for the financial year ended March 31, 2026. The record date for determining dividend entitlement is September 4, 2026. Payment of the dividend, if approved, will be made within 30 days of the AGM. — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_06082026151835_IntimationAGMdateandRecorddate.pdf)
- 2026-08-06 — Generic Announcement: Emcure Pharmaceuticals Limited has made the audio recording of its Q1 FY27 earnings call, held on August 06, 2026, available on its website. This disclosure follows a previous intimation on July 15, 2026, and complies with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_06082026215737_AudioRecordingEarningCallQ1FY27.pdf)
- 2026-08-06 — Earnings Presentation: Emcure Pharmaceuticals Limited reported unaudited financial results for the quarter ended June 30, 2026, with revenue of INR 25,804 million, a 22.8% year-over-year increase. EBITDA was INR 5,080 million with a 19.7% margin, and Profit After Tax (PAT) was INR 2,925 million with an 11.3% margin. International business revenue grew 34.2% year-over-year, contributing 58% of total revenue. The company also announced leadership changes, with Mr. Satish Mehta to become Chairman and Mr. Samit Mehta appointed COO. — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_06082026135536_IntimationOfInvestorPresentation.pdf)
- 2026-07-22 — Generic Announcement: Emcure Pharmaceuticals Limited has completed the acquisition of 663,865 equity shares, representing 12.05% of Gennova Biopharmaceuticals Limited, for an aggregate consideration of Rs. 2,318.7 Million. This acquisition, finalized on July 21, 2026, makes Gennova a wholly owned subsidiary of Emcure Pharmaceuticals Limited. — [Official attachment](https://nsearchives.nseindia.com/corporate/EMCURE_22072026181325_EPLCompletionofGBLAcquisitionsd.pdf)

## News and market events

- 2026-09-16 — MONEYCONTROL: **Trade Spotlight: How should you trade Dabur India, ACME Solar Holdings, Emcure Pharma, Aegis Vopak Terminals, Prime Focus, and others on September 16?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-dabur-india-acme-solar-holdings-emcure-pharma-aegis-vopak-terminals-prime-focus-and-others-on-september-16-14030707.html)
- 2026-09-16 — Mint: **Nifty faces risk of retesting June lows as rising US yields and crude oil prices remain key headwinds** — Nifty eventually closed 279.50 points lower at 23,118.60, marking its lowest closing level since April 6, 2026 — [Source](https://www.livemint.com/market/stock-market-news/nifty-faces-risk-of-retesting-june-lows-as-rising-us-yields-and-crude-oil-prices-remain-key-headwinds-11789519992652.html)
- 2026-09-15 — Times of India: **Stock Market Live Updates Today: BSE Sensex rallies 400 points, Nifty climbs above 23,500 in early trade - The Times of India** — Asian shares remained under pressure as investors assessed escalating Middle East tensions, higher oil prices and elevated bond yields ahead of key c — [Source](https://timesofindia.indiatimes.com/business/india-business/sensex-stock-market-today-15-september-2026-live-updates-nse-bse-gift-nifty-50-top-gainers-losers-mcx-stocks-in-focus-market-news/liveblog/134250928.cms)
- 2026-09-15 — Times of India: **Top stocks to buy: Stock recommendations for September 15, 2026 week - check list** — India Business News: Stock market recommendations: Emcure Pharmaceuticals, and Cholamandalam Investment & Finance Company Ltd - Motilal Oswal Wealth Management Researc. — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-september-15-2026-week-emcure-pharmaceuticals-cholamandalam-investment-finance-company-stocks-to-buy-today/articleshow/134250782.cms)
- 2026-09-14 — Times of India: **Stocks to buy: What's the outlook for Nifty for September 15-September 18 week? Check list of top stock recommendations** — India Business News: Stock market recommendations: Emcure Pharmaceuticals, and VA Tech Wabag are the top stocks to buy on September 15, 2026, recommends Sudeep Shah, Head . — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stocks-to-buy-this-week-september-15-to-september-18-stock-recommendations-emcure-pharmaceuticals-va-tech-wabag/articleshow/134243598.cms)
- 2026-09-12 — Economic Times: **F&O Talk: Nifty has slipped below its crucial support, says Sudeep Shah; picks 5 stocks for next week** — After a turbulent trading day, Indian stock indices bounced back significantly as oil prices and bond yields eased. The Sensex and Nifty ended with modest declines, having experienced deeper dips earlier. Previous climbs in crude oil prices and geopolitical issues had weighed down on investor confidence. Analysts suggest maintaining caution and closely watching Niftys support and resistance levels, highlighting particular metal stocks and equities to watch for the week ahead. — [Source](https://economictimes.indiatimes.com/markets/expert-view/fo-talk-nifty-has-slipped-below-its-crucial-support-says-sudeep-shah-picks-5-stocks-for-next-week/articleshow/134119208.cms)
- 2026-09-07 — BUSINESSTODAY: **Adani Power, Samman, IMFA, UBL, Emcure among stocks with fresh brokerage interest for upto 140% rise** — Adani Power target price, Physicswallah target price, SEAMEC target price, UBL target price, Emcure Pharma target price, Cera Sanitary target price, Kissht target price, IMFA target price, Leela Hotels target price, Apollo Micro target price, Sammaan Capital target price, Adani Power, Physicswallah, SEAMEC, United Breweries, Emcure Pharmaceuticals, Cera Sanitaryware, OnEMI Technology Solutions, Indian Metals & Ferro Alloys, Leela Palaces Hotels & Resorts, Apollo Micro Systems, Sammaan Capital, Adani Power target price, Physicswallah target price, SEAMEC target price, UBL target price, Emcure Pharma target price, Cera Sanitary target price, Kissht target price, IMFA target price, Leela Hotels target price, Apollo Micro target price, Sammaan Capital target price, Motilal Oswal, Choice Institutional Equities, ICICIDirect Research, JM Financial, 360 One Capital, Antique Stock Broking, Systematix Institutional Equities, Ventura — [Source](https://www.businesstoday.in/markets/stocks/story/adani-power-samman-imfa-ubl-emcure-among-stocks-with-fresh-brokerage-interest-for-upto-140-rise-553571-2026-09-07)
- 2026-09-04 — The Hindu: **Broker’s call: Emcure Pharma (Buy)** — ICICI Direct — [Source](https://www.thehindubusinessline.com/markets/brokers-call-emcure-pharma-buy/article71427726.ece)
- 2026-08-24 — Economic Times: **DRL, Emcure get approval to make breakthrough HIV drug** — India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lenacapavir-drl-emcure-get-approval-to-make-breakthrough-hiv-drug/articleshow/133476844.cms)
- 2026-08-10 — MONEYCONTROL: **Taking Stock: Sensex, Nifty end flat in rangebound trade; realty shines, PSU banks drag** — Taking Stock,Sesnex,Nifty — [Source](https://www.moneycontrol.com/news/business/markets/taking-stock-sensex-nifty-end-flat-in-rangebound-trade-realty-shines-psu-banks-drag-14000264.html)
- 2026-08-10 — BUSINESSTODAY: **Top stocks in news: Titan, Ola, PFC, Oil India, Kaynes, Anant Raj, Godawari Power, Akums** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Titan Company, Ola Electric Mobility, Power Finance Corporation, Oil India, Kaynes Technology India, Anant Raj, Hitachi Energy India, Raymond Realty, Azad Engineering, Godawari Power & Ispat, Akums Drugs and Pharmaceuticals, Entero Healthcare Solutions, Nitin Spinners, Ambika Cotton Mills — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-titan-ola-pfc-oil-india-kaynes-anant-raj-godawari-power-akums-548205-2026-08-10)
- 2026-08-07 — The Hindu: **Sensex today | Stock Market Live: Sensex down 250 pts, Nifty touches 24,600 on rising oil prices; IT stocks lead Nifty gains as financials bleed** — Sensex, Nifty, Share Prices Live: Sensex traded 344.86 pts or 0.44% lower at 78,609.90 at 9.17 am after opening at  78,516.08 from the previous close of 78,954.76. Nifty 50 declined 50.60 pts or 0.21% to 24,585.40. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-7th-august-2026/article71314561.ece)
- 2026-08-07 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: GIFT Nifty trades over 90 pts lower; Biocon in focus** — Sensex Today | Stock Market Live Updates: The index holding on to 24,500 levels on the downside is something that the bulls will be pleased with as analysts believe it is forming a base for a move, first towards 24,800, and eventually to record levels. Crude oil prices though, have staged a minor rebound overnight with brent returning to above $80 a barrel. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-cas-tata-hero-pgel-lic-sci-sbi-ncc-premier-crompton-midcaps-share-price-liveblog-19963799.htm)
- 2026-08-06 — Economic Times: **Emcure Pharma Q1 profit jumps 36%, revenue rises 23%; appoints Samit Mehta as COO** — "We have begun FY27, the second year of our five-year plan—on a strong footing. FY26 was about putting the building blocks in place across teams, portfolio, integration and operating discipline. FY27 is about delivery, and Q1 is an encouraging early signal,” said Satish Mehta, Managing Director and CEO Emcure Pharmaceuticals. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/emcure-pharma-q1-profit-jumps-36-revenue-rises-23-appoints-samit-mehta-as-coo/articleshow/133011682.cms)
- 2026-08-06 — CNBC-TV18: **From Trent and Britannia to LIC: Thursday's biggest earnings winners, losers and surprises** — Retail, FMCG, insurance and pharma dominated another busy day of results, but the biggest market moves came from the details hidden beneath the headline numbers. — [Source](https://www.cnbctv18.com/market/earnings/trent-britannia-lic-earnings-aug-6-biggest-q1-results-winners-losers-and-surprises-19963637.htm)
- 2026-08-06 — CNBC-TV18: **Emcure Pharmaceuticals Q1 Results: Net profit rises 42%, international business aids topline growth** — Emcure Pharma's International revenue rose 34.2% to ₹1,485.1 crore, driven by growth across Europe, Canada and the Rest of the World markets, aided by new product launches and favourable currency movements. — [Source](https://www.cnbctv18.com/market/emcure-pharmaceuticals-q1-results-profit-international-biz-revenue-growth-margins-outlook-share-price-returns-19963243.htm)
- 2026-08-06 — FREEPRESSJOURNAL.IN: **Emcure Pharma Q1 PAT Rises 36% To ₹292.49 Crore, Revenue Up 22.8%** — Emcure Pharmaceuticals reported a significant increase in its consolidated net profit for the first quarter of fiscal year 2027, rising 36.2% year-on-year, alongside a 22.8% growth in revenue from operations — [Source](https://www.freepressjournal.in/business/emcure-pharma-q1-pat-rises-36-to-29249-crore-revenue-up-228)
- 2026-08-06 — CNBC-TV18: **Q1 Results LIVE Updates: Trent profit up 26%; Emcure shares at day's lows despite 42% profit hike** — Q1 Results LIVE Updates; Trent, Britannia, Lupin, Samvardhana Motherson, Apollo Tyres, Blue Star, Premier Energies, HCC, NCC, PG Electroplast, Emcure Pharma, Firstsource Solutions are some of the many companies that will be reporting their results during the course of Thursday's trading session on Dalal Street. Result reactions today come from PB Fintech, Aurobindo Pharma, Cummins India, GE Vernova T&D, ION Exchange and many others. Watch this space for all the LIVE Q1 result updates, management and brokerage commentary along with stock moves. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-cummins-ge-vernova-td-pb-fintech-trent-britannia-hero-lupin-samil-pgel-apollo-tyres-sci-ncc-hcc-premier-energies-share-price-liveblog-19962840.htm)
- 2026-08-06 — MONEYCONTROL: **Emcure's profit jumps 36% on strong overseas business, operating leverage in Q1FY27** — Emcure, Zuventus, Q1 earnings, Satish Mehta, Samit Mehta, Europe — [Source](https://www.moneycontrol.com/news/business/earnings/emcure-s-profit-jumps-36-on-strong-overseas-business-operating-leverage-in-q1fy27-13996503.html)
- 2026-08-06 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty above 24,650; Firstsource falls 13% after results** — Sensex Today | Stock Market LIVE Updates: We are the halfway mark, and the market contiue to remain largely flat. The markets are once again moving on a cautious note, with the Nifty trading flat around the 24,600 mark. The Nifty Bank is also in the same state, trying to scale the 58,000 mark. Titan, Reliance and Eternal are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-hdfc-bank-aurobindo-cummins-biocon-pb-fintech-lic-trent-share-price-liveblog-19962846.htm)
- 2026-07-25 — Times of India: **ICMR hands over homegrown cervical pre-cancer treatment, vaccine technologies to pharma firms** — India News: NEW DELHI: A potential new treatment for cervical pre-cancer and two next-generation vaccines against typhoid and other gut infections have moved a st. — [Source](https://timesofindia.indiatimes.com/india/icmr-hands-over-homegrown-cervical-pre-cancer-treatment-vaccine-technologies-to-pharma-firms/articleshow/132620833.cms)
- 2026-07-21 — The Hindu: **Why these 10 stocks will be in focus on Tuesday** — TAFE, CDSL, SPML Infra, Emcure Pharma, Redington, Wanbury, RITES, KCP Sugar, Mafatlal and Monarch Surveyors — [Source](https://www.thehindubusinessline.com/markets/why-these-10-stocks-will-be-in-focus-on-tuesday/article71247877.ece)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical products globally.

### Business segments
- **Pharmaceutical Formulations:** Develops and markets a wide array of formulations including tablets, capsules, injectables, and biotechnology products across therapeutic areas like gynecology, cardiology, oncology, blood-related disorders, and HIV antivirals.
- **Active Pharmaceutical Ingredients (APIs):** Produces active pharmaceutical ingredients (APIs) that are essential components for various pharmaceutical formulations.
- **Biologics (via Gennova Biopharmaceuticals Ltd.):** Focuses on advancing biologics for life-threatening diseases, with a specialization in cardiology, nephrology, and oncology.

### Competitive strengths
- Diverse product portfolio spanning multiple therapeutic areas.
- Global operational footprint across key international markets.
- Focus on developing and manufacturing both pharmaceutical formulations and active pharmaceutical ingredients (APIs).
- Specialization in advanced biologics through a dedicated subsidiary.

## Related stocks

- [360ONE (Financial Services)](https://faxioms.com/stocks/360one) — +1.96%
- [3MINDIA (Diversified)](https://faxioms.com/stocks/3mindia) — +5.50%
- [AADHARHFC](https://faxioms.com/stocks/aadharhfc) — -1.42%
- [AARTIIND](https://faxioms.com/stocks/aartiind) — +3.19%
- [AAVAS](https://faxioms.com/stocks/aavas) — -1.07%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/emcure
Markdown representation: https://faxioms.com/stocks/emcure?render=md